|
Título:
|
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
|
|
Autores:
|
Wheeler, D.C. ;
Stefansson, B.V. ;
Batiushin, M. ;
Bilchenko, O. ;
Cherney, D.Z.I. ;
Chertow, G.M. ;
Douthat, W. ;
Dwyer, J.P. ;
Escudero, E. ;
Pecoits-Filho, R. ;
Furuland, H. ;
Górriz, J.L. ;
Greene, T. ;
Haller, H. ;
Hou, F.F. ;
Kang, S.-W. ;
Isidto, R. ;
Khullar, D. ;
Mark, P.B. ;
McMurray, J.J.V. ;
Kashihara, N. ;
Nowicki, M. ;
Persson, F. ;
Correa-Rotter, R. ;
Rossing, P. ;
Toto, R.D. ;
Umanath, K. ;
Van Bui, P. ;
Wittmann, I. ;
Lindberg, M. ;
Sjöström, C.D. ;
Langkilde, A.M. ;
Heerspink, H.J.L.
|
|
Tipo de documento:
|
texto impreso
|
|
Editorial:
|
NLM (Medline), 2020-12-14T16:11:09Z
|
|
Nota general:
|
info:eu-repo/semantics/restrictedAccess
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
|
|
Idiomas:
|
Inglés
|
|
Palabras clave:
|
Editados por otras instituciones
,
Artículos
,
Artículos en revistas indizadas
|
|
Resumen:
|
BACKGROUND: The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). This analysis reports the baseline characteristics of those recruited, comparing them with those enrolled in other trials. METHODS: In DAPA-CKD, 4304 participants with a urinary albumin:creatinine ratio (UACR) ?200?mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75?mL/min/1.73?m2 were randomized to dapagliflozin 10?mg once daily or placebo. Mean eGFR was 43.1?mL/min/1.73?m2 and median UACR was 949?mg/g (108?mg/mmol). RESULTS: Overall, 2906 participants (68%) had a diagnosis of T2D and of these, 396 had CKD ascribed to a cause other than diabetes. The most common causes of CKD after diabetes (n?=?2510) were ischaemic/hypertensive nephropathy (n?=?687) and chronic glomerulonephritis (n?=?695), of which immunoglobulin A nephropathy (n?=?270) was the most common. A total of 4174 participants (97%) were receiving an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, 1882 (43.7%) diuretics, 229 (5.3%) mineralocorticoid receptor antagonists and 122 (2.8%) glucagon-like peptide 1 receptor agonists. In contrast to the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), the DAPA-CKD trial enrolled participants with CKD due to diabetes and to causes other than diabetes. The mean eGFR of participants in the DAPA-CKD trial was 13.1?mL/min/1.73?m2 lower than in CREDENCE, similar to that in the Finerenone in Reducing Kidney Failure and Disease Progression in DKD (FIDELIO-DKD) trial and the Study Of diabetic Nephropathy with AtRasentan (SONAR). CONCLUSIONS: Participants with a wide range of underlying kidney diseases receiving renin-angiotensin system blocking therapy have been enrolled in the DAPA-CKD trial. The trial will examine the efficacy and safety of dapagliflozin in participants with CKD Stages 2-4 and increased albuminuria, with and without T2D. © The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.
|
|
En línea:
|
http://repositorio.upch.edu.pe/handle/upch/8855
|
